ANDA 203217, held by Teva Pharms USA. Risedronate Sodium.
As of Nov 16, 2026, ANDA 203217 (Risedronate Sodium), held by Teva Pharms USA, was first approved by FDA on May 18, 2015, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 18, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Risedronate Sodium35MG ยท tablet, delayed release;oral | Risedronate Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters